# US 6,727,227 B1 · Tetrapetide revealing geroprotective effect, pharmacological substance on its basis, and the method of its application

> Agents: this data is available as JSON from the patentgrep API and MCP server — see https://patentgrep.com/llms.txt

- Number: US 6,727,227 B1
- Document ID: US6727227B1
- Status: Granted
- Kind: B1
- Application number: 09/959,852
- Filed: 2002-03-06
- Granted: 2004-04-27
- Earliest claimed: 2002-03-06
- Assignees: Obschestvo S Ogranichennoi Otvetstven-Nostiju “Klinika Instituta {overscore (B)}ioregulyatsii Gerontologii”
- Inventors: Vladimir K. Khavinson
- Web page: https://patentgrep.com/patent/US6727227B1

## CPC

- C07K 5/1008: {the side chain containing 0 or 1 carbon atoms, i.e. Gly, Ala}
- A61P 1/00: Drugs for disorders of the alimentary tract or the digestive system
- A61P 3/00: Drugs for disorders of the metabolism (of the blood or the extracellular fluid A61P7/00)
- A61P 9/00: Drugs for disorders of the cardiovascular system
- A61P 11/00: Drugs for disorders of the respiratory system
- A61P 11/06: Antiasthmatics
- A61P 19/00: Drugs for skeletal disorders
- A61P 39/06: Free radical scavengers or antioxidants
- A61P 43/00: Drugs for specific purposes, not provided for in groups A61P1/00-A61P41/00
- A61K 38/00: Medicinal preparations containing peptides (peptides containing beta-lactam rings A61K31/00; cyclic dipeptides not having in their molecule any other peptide link than those which form their ring, e.g. piperazine-2,5-diones, A61K31/00; ergot alkaloids of the cyclic peptide type A61K31/48; containing macromolecular compounds having statistically distributed amino acid units A61K31/74; medicinal preparations containing antigens or antibodies A61K39/00; medicinal preparations characterised by the non-active ingredients, e.g. peptides as drug carriers, A61K47/00)
- C07K: PEPTIDES (peptides in foodstuffs A23; obtaining protein compositions for foodstuffs, working-up proteins for foodstuffs A23J; preparations for medicinal purposes A61K; peptides containing beta-lactam rings C07D; cyclic dipeptides not having in their molecule any other peptide link than those which form their ring, e.g. piperazine-2,5-diones, C07D; ergot alkaloids of the cyclic peptide type C07D519/02; macromolecular compounds having statistically distributed amino acid units in their molecules, i.e. when the preparation does not provide for a specific; but for a random sequence of the amino acid units, homopolyamides and block copolyamides derived from amino acids C08G69/00; macromolecular products derived from proteins C08H1/00; preparation of glue or gelatine C09H; single cell proteins, enzymes C12N; genetic engineering processes for obtaining peptides C12N15/00; compositions for measuring or testing processes involving enzymes C12Q; investigation or analysis of biological material G01N33/00)
- A61P: SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61K: PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES (devices or methods specially adapted for bringing pharmaceutical products into particular physical or administering forms A61J3/00; chemical aspects of, or use of materials for deodorisation of air, for disinfection or sterilisation, or for bandages, dressings, absorbent pads or surgical articles A61L; soap compositions C11D)

## Abstract

Tetrapeptide L-alanyl-L-glutamyl-L-aspartyl-glycine (SEQ ID NO: 1) of the general formula L-Ala-L-Glu-L-Asp-Gly (SEQ ID NO: 1) is proposed as a biologically active compound with a geroprotective effect. The use of L-Ala-L-Glu-L-Asp-Gly (SEQ ID NO: 1) tetrapeptide in medicine is proposed for preparing a substance displaying a geroprotective effect. There is proposed a pharmacological substance, which contains as its active base an effective amount of tetrapeptide of the formula L-alanyl-L-glutamyl-L-aspartyl-glycine (L-Ala-L-Glu-L-Asp-Gly) (SEQ ID NO: 1) or its salts of the amino group (acetate, hydrochloride, oxalate) and of carboxyl groups (the salts of metals-Sodium, Potassium, Calcium, Lithium, Zinc, Magnesium, and also the salts of organic and inorganic cations-ammonium and triethylammonium). The substance is proposed for parenteral, intranasal, oral administration, and local application. With respect to the invention, the method of premature ageing prevention involves prophylactic and/or therapeutic administration to a patient of the pharmacological substance in doses of 0.01 to 100 μg/kg of the body weight at least once a day for a period necessary for the achievement of a therapeutic effect.

## Claims

### Claim 1

Tetrapeptide L-alanyl-L-glutamyl-L-aspartyl-glycine (SEQ ID NO: 1) of the general formula L-Ala-L-Glu-L-Asp-Gly (SEQ ID NO: 1).

### Claim 2

A pharmacological substance, containing an active base and a pharmacologically admissible carrier, wherein said active base comprises an effective amount of L-Ala-L-Glu-L-Asp-Gly (SEQ ID NO: 1) tetrapeptide or its salts.

### Claim 3 (depends on 2)

The substance described in claim 2, wherein said salts are salts of amino groups and are selected from the group consisting of acetate, hydrochloride, and oxalate.

### Claim 4 (depends on 2)

The substance described in claim 2, wherein said salts are salts of carboxyl groups, selected from the group consisting of sodium, potassium, calcium, lithium, zinc, and magnesium.

### Claim 5 (depends on 2)

The substance described in claim 2, wherein said substance is presented in a form suitable for parenteral administration.

### Claim 6 (depends on 2)

The substance described in claim 2, wherein said substance is presented in a form suitable for intranasal administration.

### Claim 7 (depends on 2)

The substance described in claim 2, wherein said substance is presented in a form suitable for oral administration.

### Claim 8 (depends on 2)

The substance described in claim 2, wherein said substance is presented in a form suitable for local application.

### Claim 9

A method of treating symptoms of premature ageing in a patient in need thereof comprising the step of administering to said patient a pharmacological substance comprising L-Ala-L-Glu-L-Asp-Gly tetrapeptide (SEQ ID NO: 1) or its salts in an amount sufficient to prevent said symptoms of premature ageing.

### Claim 10

A method for increasing superoxide dismutase activity in a subject in need thereof, comprising the step of
administering to said subject an amount of the tetrapeptide L-Ala-L-Glu-L-Asp-Gly (SEQ ID NO: 1) or its salts sufficient to cause an increase in superoxide dismutase activity in said subject.

### Claim 11

A method for decreasing lipid peroxide oxidation products in a subject in need thereof, comprising the step of
administering to said subject an amount of the tetrapeptide L-Ala-L-Glu-L-Asp-Gly (SEQ ID NO: 1) or its salts sufficient to decrease lipid peroxide oxidation products in said subject.

### Claim 12

A method for reducing asthma symptoms in a patient in need thereof, comprising the step of
administering to said patient an amount of the tetrapeptide L-Ala-L-Glu-L-Asp-Gly (SEQ ID NO: 1) or its salts sufficient to reduce asthma symptoms in said subject.

### Claim 13

A method for increasing melatonin production in a subject in need thereof, comprising the step of
administering to said subject an amount of the tetrapeptide L-Ala-L-Glu-L-Asp-Gly (SEQ ID NO: 1) or its salts sufficient to increase melatonin production in said subject.

### Claim 14 (depends on 2)

The substance described in claim 2 wherein said salts are selected from the group consisting of salts of organic cations and salts of inorganic cations.

### Claim 15 (depends on 2)

The substance described in claim 2 wherein said salts are selected from the group consisting of ammonium and triethylammonium.

### Claim 16 (depends on 9)

The method of claim 9 wherein said symptoms are selected from the group consisting of a decrease in superoxide dismutase activity, an increase in lipid peroxide oxidation products and a decrease in melatonin production.

### Claim 17 (depends on 9)

The method of claim 9 wherein said salts are salts of amino groups and are selected from the group consisting of the salts of acetate, hydrochloride, and oxalate.

### Claim 18 (depends on 9)

The method of claim 9 wherein said salts are salts of carboxyl groups and are selected from the group consisting of the salts of sodium, potassium, calcium, lithium, zinc, and magnesium.

### Claim 19 (depends on 9)

The method of claim 9 wherein said salts are selected from the group consisting of salts of organic cations and salts of inorganic cations.

### Claim 20 (depends on 9)

The method of claim 9 wherein said salts are selected from the group consisting of ammonium and triethylammonium.
